Drug profile · INN
danicopan
VOYDEYA
danicopan (VOYDEYA) is a complement factor d inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — danicopan
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- ORAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
danicopan (VOYDEYA) is a complement factor d inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Complement factor D inhibitor
Primary target: Complement factor D
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is danicopan?
danicopan (VOYDEYA) is a complement factor d inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for danicopan?
VOYDEYA is a marketed brand name for danicopan. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of danicopan?
danicopan has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.